首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines
【24h】

A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines

机译:用溶解微针贴片封装M2E疫苗的促进皮肤疫苗接种促进常规流感疫苗的保护效果

获取原文
获取原文并翻译 | 示例
           

摘要

The biodegradable microneedle patch (MNP) is a novel technology for vaccine delivery that could improve the immunogenicity of vaccines. To broaden the protective efficiency of conventional influenza vaccines, a new 4M2e-tFliC fusion protein construct containing M2e sequences from different subtypes was generated. Purified fusion protein was encapsulate into MNPs with a biocompatible polymer for use as a boosting vaccine. The results demonstrated that mice receiving a conventional inactivated vaccine followed by a skin-applied dissolving 4M2e-tFliC MNP boost could better maintain the humoral antibody response than that by the conventional vaccine-prime alone. Compared with an intramuscular injection boost, mice receiving the MNP boost showed significantly enhanced cellular immune responses, hemagglutination-inhibition (HAI) titers, and neutralization titers. Increased frequency of antigen-specific plasma cells and long-lived bone marrow plasma cells was detected in the MNP boosted group as well, indicating that skin vaccination with 4M2e-tFliC facilitated a long-term antibody-mediated immunity. The 4M2e-tFliC MNP-boosted group also possessed enhanced protection against high lethal dose challenges against homologous A/PR/8/34 and A/Aichi/2/68 viruses and protection for a majority of immunized mice against a heterologous A/California/07/2009 H1N1 virus. High levels of M2e specific immune responses were observed in the 4M2e-tFliC MNP-boosted group as well. These results demonstrate that a skin-applied 4M2e-tFliC MNP boosting immunization to seasonal vaccine recipients may be a rapid approach for increasing the protective efficacy of seasonal vaccines in response to a significant drift seen in circulating viruses. The results also provide a new perspective for future exploration of universal influenza vaccines.
机译:可生物降解的微针贴片(MNP)是一种用于疫苗递送的新技术,可以改善疫苗的免疫原性。为了拓宽常规流感疫苗的保护效率,产生了含有不同亚型的M2E序列的新的4M2E-TFLIC融合蛋白构建体。将纯化的融合蛋白包封在具有生物相容性聚合物中的MnP中,用作促进疫苗。结果表明,接受常规的灭活疫苗的小鼠随后是皮肤施加的溶解4M2E-TFLIC MNP Boost可以更好地维持比常规疫苗 - 单独的疫苗抗体反应。与肌内注射升压相比,接受MNP Boost的小鼠显示出显着增强的细胞免疫应答,血凝抑制(HAI)滴度和中和滴度。在MNP升压组中检测到抗原特异性血浆细胞和长寿命骨髓细胞的增加的频率,表明用4M2E-TFLIC的皮肤疫苗接种促进了长期抗体介导的免疫。 4M2E-TFLIC MNP促进组还具有针对同源A / PR / 8/34和A / AICHI / 2/68病毒的高致死剂量挑战的增强保护,以及针对异源A /加利福尼亚州的大多数免疫小鼠的病毒和保护07/2009 H1N1病毒。在4M2E-TFLIC MNP升压组中观察到高水平的M2E特异性免疫应答。这些结果表明,对季节性疫苗接种者的皮肤施加的4M2E-TFLIC MNP促进免疫可能是增加季节性疫苗的保护效果的快速方法,响应于循环病毒中所见的显着漂移。结果还提供了未来探索普遍流感疫苗的新视角。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号